Latest Expert Opinions

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
February 22, 2017

(A Top Pick June 22/16. Up 17.44%.) They are the dominant medical insurer. The transition from straight Medicare to Medicare Advantage will be a positive tailwind for them. There are some tax benefits coming down the pipeline that will be positive for them. The only US medical insurer that is integrated with its pharmacy benefit manager, which is proving to be positive.

(A Top Pick June 22/16. Up 17.44%.) They are the dominant medical insurer. The transition from straight Medicare to Medicare Advantage will be a positive tailwind for them. There are some tax benefits coming down the pipeline that will be positive for them. The only US medical insurer that is integrated with its pharmacy benefit manager, which is proving to be positive.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$160.570
Owned
Yes
COMMENT
COMMENT
February 22, 2017

This is his company’s fund. It hedges its currency and has 20 large cap global healthcare companies. One of the greatest risks in the market right now is individual stock risk.

This is his company’s fund. It hedges its currency and has 20 large cap global healthcare companies. One of the greatest risks in the market right now is individual stock risk.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$8.290
Owned
Yes
COMMENT
COMMENT
February 22, 2017

This has everything you can think of that is tools related, from your head all the way down to your toes; cardiovascular, stent. The dominant player in medical technologies. Trading at 17X next year’s earnings. Had a hiccup last quarter, but all they had to do was show that things were back on track. He likes this.

Medtronic Inc (MDT-N)
February 22, 2017

This has everything you can think of that is tools related, from your head all the way down to your toes; cardiovascular, stent. The dominant player in medical technologies. Trading at 17X next year’s earnings. Had a hiccup last quarter, but all they had to do was show that things were back on track. He likes this.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$79.620
Owned
Yes
BUY
BUY
February 22, 2017

This is a long-term Hold. He recently added to his holdings. This is your hip, knees, ankles, feet, prosthetics. You are paying a little bit more for their growth. This is going to be the wave of the future. Feels they are capturing market share.

Stryker Corp. (SYK-N)
February 22, 2017

This is a long-term Hold. He recently added to his holdings. This is your hip, knees, ankles, feet, prosthetics. You are paying a little bit more for their growth. This is going to be the wave of the future. Feels they are capturing market share.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$127.290
Owned
Yes
COMMENT
COMMENT
February 22, 2017

They have a pipeline of drugs, but the clear driver is going to be its immuno oncology platform. When you look through to 2020, that is going to be about 55% of its revenues. They have their combo with Opdivo Oeuvre which is coming out later this year. Don’t be naïve to the risks that are associated here. Roche is coming in 2nd line lung cancer and are capturing market share. This will trade off of the other companies. He owns all 3.

They have a pipeline of drugs, but the clear driver is going to be its immuno oncology platform. When you look through to 2020, that is going to be about 55% of its revenues. They have their combo with Opdivo Oeuvre which is coming out later this year. Don’t be naïve to the risks that are associated here. Roche is coming in 2nd line lung cancer and are capturing market share. This will trade off of the other companies. He owns all 3.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$55.350
Owned
Yes
HOLD
HOLD
February 22, 2017

He is on the more optimistic side of this company. It has Humira, the largest selling drug in inflammatory related diseases. Because of that, they are going off patent. Everybody knows there is going to be competition for Humira, which he feels is being factored in to their forward earnings. They’ve known this too and have been building out their pipelines. He likes their 4% dividend. PE is going from 11 to 9 next year, a one-time PEG ratio. You are not paying a lot for the growth.

AbbVie Inc. (ABBV-N)
February 22, 2017

He is on the more optimistic side of this company. It has Humira, the largest selling drug in inflammatory related diseases. Because of that, they are going off patent. Everybody knows there is going to be competition for Humira, which he feels is being factored in to their forward earnings. They’ve known this too and have been building out their pipelines. He likes their 4% dividend. PE is going from 11 to 9 next year, a one-time PEG ratio. You are not paying a lot for the growth.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$61.360
Owned
Yes
COMMENT
COMMENT
February 22, 2017

He likes this and their diversified business line. They’ve got vaccines, pharmaceuticals and their consumer health. Their pipeline tends to be a little bit earlier. Advair does end up as a generic this year, and have fully indicated that in their guidance. The upside could be if we don’t see that generic hit the market this year. There have been some delays in other generic hitting the market. That would be pure upside. Good yield.

GlaxoSmithKline PLC (GSK-N)
February 22, 2017

He likes this and their diversified business line. They’ve got vaccines, pharmaceuticals and their consumer health. Their pipeline tends to be a little bit earlier. Advair does end up as a generic this year, and have fully indicated that in their guidance. The upside could be if we don’t see that generic hit the market this year. There have been some delays in other generic hitting the market. That would be pure upside. Good yield.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$41.030
Owned
Yes